The role of protons in modern and biologically-guided radiotherapy

Acta Oncologica

Volumn 49, Issue 7, 2010, Pages 1124-1131

  Nyström, Håkan ^a,b  

^a Skandion Clinic   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON;

CANCER RADIOTHERAPY; CANCER SURVIVAL; MORBIDITY; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RATING SCALE; TUMOR LOCALIZATION; TUMOR VOLUME;

ADAPTATION, PHYSIOLOGICAL; DOSE FRACTIONATION; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROTONS; RADIATION ONCOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 77956592675     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.498436     Document Type: Note

References (43)

1. Grau C, Muren LP, Høyer M, Lindegaard J, Overgaard J. Image-guided adaptive radiotherapy-integration of biology and technology to improve clinical outcome. Acta Oncol 2008;47:1182-1185
2. Da şu A. Treatment planning optimisation based on imaging tumour proliferation and cell density. Acta Oncol 2008; 47:1221-1228
3. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21: 109-122
4. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10-9.
5. Kutcher GJ. Quantitative plan evaluation: TCP/NTCP models. Front Radiat Ther Oncol 1996;29:67-80.
6. Baumann M, Petersen C, Krause M. TCP and NTCP in preclinical and clinical research in Europe. Rays 2005;30: 121-126
7. Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys 1997;24: 103-110
8. Wang JZ, Mayr NA, Yuh WT. Behind EUD. Acta Oncol 2008;47:971-972
9. Levin-Plotnik D, Hamilton RJ. Optimization of tumour control probability for heterogeneous tumours in fractionated radiotherapy treatment protocols. Phys Med Biol 2004; 49:407-424
10. Webb S. Optimum parameters in a model for tumour control probability including interpatient heterogeneity. Phys Med Biol 1994;39:1895-1914
11. Webb S, Nahum AE. A model for calculating tumour control probability in radiotherapy including the effects of inhomo-geneous distributions of dose and clonogenic cell density. Phys Med Biol 1993;38:653-666
12. Hall EJ. Dose-painting by numbers: A feasible approach? Lancet Oncol 2005;6:66.
13. Bentzen SM. Theragnostic imaging for radiation oncology: Dose-painting by numbers. Lancet Oncol 2005;6:12-17
14. Fenwick JD, Nahum AE, Malik ZI, Eswar CV, Hatton MQ, Laurencejj VM, et al. Escalation and intensifi cation of radiotherapy for stage III non-small cell lung cancer: Opportunities for treatment improvement. Clin Oncol 2009; 21:343-360
15. van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010;28:1380-1386
16. Miles EA, Clark CH, Urbano TG, Bidmead M, Dearnaley DP, Harrington KJ, et al. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radi-other Oncol 2005;77:241-246
17. Lomax A. Intensity modulation methods for proton radiotherapy. Phys Med Biol 1999;44:185-205.
18. Tilly N, Johansson J, Isacsson U, Medin J, Blomquist E, Grusell E, et al. The infl uence of RBE variations in a clinical proton treatment plan for a hypopharynx cancer. Phys Med Biol 2005;50:2765-2777
19. Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: A treatment planning comparison study. Radiat Oncol 2009;4:34.
20. Zhang X, Li Y, Pan X, Xiaoqiang L, Mohan R, Komaki R, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIb non-small-cell lung cancer: A virtual clinical study. Int J Radiat Oncol Biol Phys 2010;77:357-366.
21. Ares C, Khan S, Macartain AM, Heuberger J, Goitein G, Gruber G, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: Potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys 2010; 76:685-697
22. Dowdell SJ, Metcalfe PE, Morales JE, Jackson M, Rosenfeld AB. A comparison of proton therapy and IMRT treatment plans for prostate radiotherapy. Australas Phys Eng Sci Med 2008;31:325-331
23. Muzik J, Soukup M, Alber M. Comparison of fi xed-beam IMRT, helical tomotherapy, and IMPT for selected cases. Med Phys 2008;35:1580-1592
24. Glimelius B, Ask A, Bjelkengren G, Björk-Eriksson T, Blomquist E, Johansson B, et al. Number of patients potentially eligible for proton therapy. Acta Oncol 2005;44: 836-849
25. Rijkee AG, Zoetelief J, Raaijmakers CP, Van Der Marck SC, Van Der Zee W. Assessment of induction of secondary tumours due to various radiotherapy modalities. Rad Prot Dosim 2006;118:219-226
26. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009;91:4-15.
27. Mu X, Björk-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 2005;44:554-562
28. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
29. Verellen D, Vanhavere H. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol 1999;53:199-203.
30. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010;13:29-43.
31. Schulz RJ, Kagan AR. More precisely defi ned dose distributions are unlikely to affect cancer mortality. Med Phys 2003;30:276.
32. Blanco R, Sole ́ J, Montesinos J, Mesí a C, Algara M, Terrassa J, et al. ACROSS. Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study. Lung Cancer 2008;62:62-71.
33. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-2463
34. Pfi ster DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-1078
35. Arrieta O, Gallardo-Rinc ó n D, Villarreal-Garza C, Michel RM, Astorga-Ramos AM, Mart í nez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitab-ine and carboplatin. J Thorac Oncol 2009;4:845-852
36. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006;66: 1399-1407
37. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemo-radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006;64:692-699 (Pubitemid 43183562)
38. Das ̧u A, Toma-Das ̧u I, Olofsson J, Karlsson M. The use of risk estimation models for the induction of secondary cancers following radiotherapy. Acta Oncol 2005;44:339-347
39. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980
40. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437
41. Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, et al. Lung cancer after treatment for Hodgkin's disease: Focus on radiation effects. Radiat Res 2003;159:161-173
42. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA. 2005;102: 13040-13045
43. Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: Application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys 2005;44:235-239